Problem
A small biotech company had just acquired a new asset, a drug product that had already started phase 2 clinical studies, with phase 3 clinical trials planned toward an NDA to be submitted by the cross-functional team. The business development team was familiar with the newly acquired product from a high level. The cross-functional development team, which included nonclinical, clinical, and CMC team members, was a bit unclear about the regulatory pathway options.
Solution
A review of the development history began with a gap analysis of all the pre-IND and IND submission components. The gap analysis reviewed the formal and informal communication paths between the previous company and the FDA, including all the email correspondence between the regulatory point person and the FDA project manager. The communication history provided vital information on the previous regulatory program and uncovered potential nonclinical, clinical, and CMC scientific options. This helped set the direction of the next steps within the development plan of the product. A review of the competitive landscape gave insight into the submission strategy and additional options toward the NDA submission strategy.
Outcome
The outcome was a more streamlined regulatory path including transparent and clear communication with the FDA, leading to an overall better solution for the client and a shorter timeline to the NDA submission. The message: Take the extra time to look at all of the development history and all of the FDA communications.
Click here to open a PDF version of this case study.